Stem cell clinics and the gap between a licensed therapy and a marketed one

What is genuinely established

Transplantation of blood-forming stem cells is long-established medicine used for specific blood disorders and certain cancers. A small number of other cell-based products have been approved in various jurisdictions for narrowly defined indications after formal review. These share the feature of having been through controlled trials with defined endpoints and subsequent regulatory assessment.

They are also delivered in specialist centres, because the procedures carry substantial risks requiring specific expertise to manage. The existence of these established therapies is what makes the broader marketing sound plausible, because the underlying science really is genuine. What does not follow is that a procedure sharing the vocabulary shares the evidence, the manufacturing controls or the oversight.

What the commercial sector generally offers

Many clinics offer preparations derived from a person's own fat or bone marrow, administered for conditions with no approved cell therapy. The preparations are typically described using the vocabulary of stem cell biology without characterisation of what the injected material contains. Cell populations obtained this way are mixtures, and the proportion of cells with the claimed properties is usually small and variable.

Because processing differs between clinics, two procedures marketed identically may deliver quite different material. This variability alone makes accumulated outcome claims gathered across such clinics nearly impossible to interpret as a single body of evidence. Cells taken from an older person also differ from those taken from a younger one, which complicates any argument built on regenerative capacity.

The registry loophole

Clinics frequently cite registration on a public trial registry as evidence of legitimacy, and registration is an administrative step. Registries record that a study has been declared, and they do not evaluate its design, its oversight or its scientific merit. Many registered studies of this kind lack a control group, which makes it impossible to distinguish treatment from natural improvement.

Where participants pay to enrol, the usual economics of a trial are reversed, and that reversal changes the incentives around recruitment. Legitimate trials of investigational treatments do not generally charge participants for the investigational element, and that difference is worth checking directly.

Documented risks

Case reports describe serious harms following unproven cell procedures, including infections, blockages and growths at injection sites. Procedures involving the eye have produced particularly severe documented outcomes, which regulators have cited in enforcement actions. Harms from procedures outside formal trials are also systematically under-reported, since there is no obligation to report them anywhere.

The absence of reported harm from a clinic therefore carries much less information than it appears to. Regulators in several jurisdictions have issued warnings and taken action against specific providers on exactly these grounds.

How to evaluate a claim

The useful questions concern what cells are being administered, how they were characterised, and what controlled evidence exists for the indication. A clinic unable to describe the composition of what it administers is not in a position to explain how it would work. Testimonials cannot substitute for controlled comparison, particularly for conditions that fluctuate naturally or respond to expectation.

Anyone considering a procedure of this kind should discuss it with a specialist not connected to the provider offering it. That is ordinary practice for any significant medical decision and it applies with particular force where the evidence base is thin.